Medical Services Advisory Committee - Applications considered
- 1516 – Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for osimertinib
- 1554 - Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in a patient with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy)
- 1559 - Endoscopic Mucosal Resection (EMR)
- 1569 - Chitosan-based cartilage biomatrix implant (BST-CarGel), in conjunction with the marrow stimulation technique (microfracture), for repair of focal cartilage defects
- 1573 - Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis
- 1575 - Autologous fat grafting (AFG) by injection, for defects arising from breast surgery, breast cancer treatment/prevention and congenital breast deformity
- 1577 - Autologous fat grafting (AFG) for treatment of burn scars, and treatment of facial defects due to craniofacial abnormalities
- 1582 - Detection of Aquaporin-4 (AQP4) antibodies in serum of cerebrospinal fluid for diagnosis of Neuromyelitis optica (NMO)
- 1586 - Transurethral water vapour ablation for benign prostate hyperplasia
- 1590 - Review of immunoglobulin use for Multifocal Motor Neuropathy (MMN)
- 1593 - Bovine bioinductive collagen implant for repair of rotator cuff tear
- 1610 - Injection of Clostridium Botulinum Type A - Haemagglutin Complex (DysportŪ) for the treatment of moderate to severe paediatric upper-limb spasticity due to cerebral palsy
- 1612 - Prostatic urethral lift procedure for men with benign prostate hyperplasia
- 1622 - Cardiac ablation devices for use in ventricular arrhythmia and supraventricular tachycardia
- 1623 - Voretigene neparvovec (Luxturna) for the treatment of biallelic RPE-65-mediated Inherited Retinal Dystrophies
- 1624 - 17p deletion testing for access to acalabrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
- 1625 - Dinutuximab beta for high-risk neuroblastoma